Skip to main content
All lobbying filings

BAYCARE HEALTH SYSTEM

BAYCARE HEALTH SYSTEM filed a Q2 report for BAYCARE HEALTH SYSTEM on July 20, 2026.

Lobbying for BAYCARE HEALTH SYSTEM

All filings by BAYCARE HEALTH SYSTEM · Everything BAYCARE HEALTH SYSTEM has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Expenses
$211,558
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Florida

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3

Participated in meetings alongside Florida Hospital Association with Representatives Castor, Bilirakis, Buchanan, and the staff of Senator Moody, Scott and Franklin. Discussed key issues pertaining to Florida's Directed Payment Program and rules impacting state directed payment models. Advocated for the Seniors Timely Access to Care Act to improve MA plan accountability. Advocated for the inclusion of 1115 UCC waiver days in the Medicaid numerator of the Medicare DSH percentage. Advocated broadly for reimbursement to improve food is medicine programs. Advocated for streamlined access to vital, innovative services such as Proton Therapy.

Submitted final IPPS rule pertaining to a variety of hospital payment and regulatory provisions. Opposed 340B rebate models and other policies to add burden and compliance to the 340B drug pricing program. Advocated against codification of a variety of price transparency provisions in the Patients Deserve Price Tags Act that exist in rule but will not meaningfully address healthcare affordability.

Advocated for protection of the existing 340B drug pricing program and concerns around a rebate model at HRSA + general preservation of the 340B drug pricing program. Also discussed the concern around exclusion of the waiver days (low income pool days in Florida).

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem